Zepbound 7.5 MG/0.5 ML pen 0.5ML
Ended Awarded
- Contract number
- SPE2DB25FTVM5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,726
Award facts
- Contract value 100% obligated
- $13,726.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois, has been awarded a delivery order valued at $13,726.44 by the Defense Logistics Agency (DLA) for Zepbound 7.5 mg/0.5 mL pen injections. The contract, issued on May 8, 2025, with an ultimate completion date of May 9, 2025, utilizes a firm fixed-price structure with no set-aside designation. The pharmaceutical products will be delivered to Conshohocken, Pennsylvania. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA, a single-award vehicle valued at $499,999,999 and valid through November 2026, which authorizes the issuance of firm fixed-price orders for a comprehensive range of pharmaceutical items supporting military healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with a robust portfolio of federal contract awards predominantly through the DLA. The company specializes in distributing branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare sites across the nation. This particular delivery order for Zepbound, a GLP-1 receptor agonist medication used in diabetes and weight management treatment, reflects the company's role in supplying specialized pharmaceutical products to support military health operations and readiness requirements.
Quick answers
Who was awarded contract SPE2DB25FTVM5?
SPE2DB25FTVM5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on May 8, 2025.
How much is contract SPE2DB25FTVM5 worth?
The government has obligated $13,726 on SPE2DB25FTVM5.
Is contract SPE2DB25FTVM5 an order under another contract?
Yes. SPE2DB25FTVM5 is a delivery order under SPE2DB20D6037, an indefinite delivery contract.
Was contract SPE2DB25FTVM5 competed?
The extent of competition for SPE2DB25FTVM5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award